Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02029443
Title ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

prolymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

diffuse large B-cell lymphoma

Therapies

Acalabrutinib

Age Groups: adult
Covered Countries USA | ITA


No variant requirements are available.